Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

Employees

Sector

Biotechnology & Medical Research

More about the company

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+6.73%	-25.81%

20-06-29	Aradigm Corporation Went Out of Business	CI
20-06-12	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI

Market Cap	4.89M 4.27M 3.95M 3.69M 6.92M 462M 6.97M 46.92M 18.26M 227M 18.34M 17.94M 789M	P/E 2016	-0.72x	P/E 2017	-9.3x
Enterprise Value	12.8M 11.18M 10.34M 9.65M 18.13M 1.21B 18.26M 123M 47.83M 595M 48.05M 47.01M 2.07B	EV / Sales 2016	73.3x	EV / Sales 2017	7.27x
Free-Float	60.28%	Yield 2016 *	-	Yield 2017	-

20-06-29	Aradigm Corporation Went Out of Business	CI
20-06-12	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI
20-04-27	Revised Disclosure Statement Conditionally Approved for Aradigm Corporation	CI
20-04-08	Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation	CI
20-03-30	Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q).	CI
20-03-30	Motion for Asset Sale Approved for Aradigm Corporation	CI
20-03-09	Bidding Procedure Approved for Aradigm Corporation	CI
20-02-20	Motion for Asset Sale Filed by Aradigm Corporation	CI
20-02-20	Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million.	CI
19-11-05	Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI
19-10-30	Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq	CI
19-10-21	Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency	CI
19-07-19	Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI

20-06-15	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-06-04	ARADIGM CORP : Other Events (form 8-K)	AQ
20-04-30	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-04-13	ARADIGM CORP : Other Events (form 8-K)	AQ
20-04-06	Aradigm : Announces Sale of Assets to Grifols, S.A.	AQ

Aradigm Corporation Stock

Stocks

ARDMQ

US0385054004

Biotechnology & Medical Research

Valuation: Aradigm Corporation

Latest news : Aradigm Corporation

Press Releases: Aradigm Corporation

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARADIGM CORPORATION	-.--%	+6.73%	-	-	702K
LONZA GROUP AG	+0.34%	+1.09%	-10.80%	-5.05%	43.13B
REVOLUTION MEDICINES, INC.	+1.65%	+2.92%	+311.44%	+559.75%	34.65B
BEONE MEDICINES AG	+1.13%	+1.62%	+5.83%	+46.60%	30.03B
IQVIA HOLDINGS INC.	-1.64%	-7.68%	+6.13%	-22.91%	28B
CELLTRION, INC.	-1.06%	-2.60%	+9.08%	+21.51%	24.45B
ASCENDIS PHARMA A/S	+0.87%	+4.25%	-	-	14.34B
MEDPACE HOLDINGS, INC.	-1.97%	-3.88%	+45.60%	+100.08%	13.14B
EUROFINS SCIENTIFIC SE	+1.54%	+0.16%	+6.65%	+8.89%	12.53B
IONIS PHARMACEUTICALS, INC.	+2.37%	+2.42%	+101.09%	+83.86%	12.25B
Average	+0.35%	+1.26%	+59.38%	+99.09%	21.25B
Weighted average by Cap.	+0.38%	+1.19%	+64.66%	+115.63%

	2016	2017
Net sales	195K 170K 158K 147K 276K 18.43M 278K 1.87M 729K 9.06M 732K 716K 31.47M	14.46M 12.64M 11.69M 10.91M 20.49M 1.37B 20.64M 139M 54.06M 672M 54.31M 53.13M 2.33B
Net income	-32.94M -28.78M -26.62M -24.85M -46.65M -3.11B -46.99M -316M -123M -1.53B -124M -121M -5.32B	-10.7M -9.35M -8.65M -8.08M -15.16M -1.01B -15.27M -103M -40.01M -497M -40.19M -39.32M -1.73B
Net Debt	-9.37M -8.19M -7.58M -7.07M -13.27M -886M -13.37M -90.02M -35.02M -435M -35.19M -34.42M -1.51B	7.91M 6.91M 6.4M 5.97M 11.21M 748M 11.29M 76M 29.57M 368M 29.71M 29.07M 1.28B